How Alphamab is differentiating in crowded cancer targets

Bringing technology twists to crowded but high-value cancer targets is the strategy that has propelled Alphamab from an antibody start-up to a multimodality, commercial oncology company with global ambitions.

Suzhou-China based Alphamab Oncology Ltd. (HKEX:9966), which launched in 2008, became the first company to gain regulatory approval of a subcutaneous PD-L1 mAb with the 2021 marketing authorization of Enweida envafolimab in China. ...